{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:30Z","timestamp":1793298930555,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:49:27Z","timestamp":1790725767000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 Inhibitors and Nephrolithiasis Risk in Adults With Type 2 Diabetes: A Systematic Review and Meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-0661","authenticated-orcid":false,"given":"Marconi","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Sakhaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0440-8404","authenticated-orcid":false,"given":"Gaspar R.","family":"Chiappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.09.007_bib1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1523-1755.2005.00516.x","article-title":"Diabetes mellitus and the risk of nephrolithiasis","volume":"68","author":"Taylor","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.eprac.2026.09.007_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00240-020-01210-w","article-title":"Trends in the prevalence of kidney stones in the United States from 2007 to 2016","volume":"49","author":"Chewcharat","year":"2021","journal-title":"Urolithiasis"},{"key":"10.1016\/j.eprac.2026.09.007_bib3","first-page":"44","article-title":"Diabetes mellitus and kidney stone formation","volume":"8","author":"Assimos","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.eprac.2026.09.007_bib4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2215\/CJN.08331109","article-title":"Metabolic basis for low urine pH in type 2 diabetes","volume":"5","author":"Maalouf","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eprac.2026.09.007_bib5","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.juro.2010.02.007","article-title":"Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers","volume":"183","author":"Eisner","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eprac.2026.09.007_bib6","doi-asserted-by":"crossref","first-page":"e3003","DOI":"10.1210\/clinem\/dgac154","article-title":"Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?","volume":"107","author":"Balasubramanian","year":"2022","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.eprac.2026.09.007_bib7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080035","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies","volume":"387","author":"McCormick","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamainternmed.2023.7660","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes","volume":"184","author":"Paik","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107808","article-title":"Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials","volume":"155","author":"Cosentino","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.09.007_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ndt\/gfae179","article-title":"SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis","volume":"40","author":"Kanbay","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eprac.2026.09.007_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib13","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated August 2024): Cochrane, 2024."},{"key":"10.1016\/j.eprac.2026.09.007_bib14","unstructured":"Lefebvre C, Glanville J, Briscoe S. Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 65 (updated August 2024): Cochrane, 2024."},{"key":"10.1016\/j.eprac.2026.09.007_bib15","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","article-title":"Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources","volume":"331","author":"Greenhalgh","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jrsm.1355","article-title":"Conduct and reporting of citation searching in Cochrane systematic reviews: A cross-sectional study","volume":"11","author":"Briscoe","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eprac.2026.09.007_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.eprac.2026.09.007_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.eprac.2026.09.007_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0895-4356(02)00443-2","article-title":"Hazard rate ratio and prospective epidemiological studies","volume":"55","author":"Symons","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eprac.2026.09.007_bib21","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.eprac.2026.09.007_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib24","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2337\/dc26-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026","volume":"49","author":"Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.09.007_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.eprac.2026.09.007_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib28","article-title":"SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era","volume":"61","author":"Grigoriou","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.eprac.2026.09.007_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.103149","article-title":"SGLT2 inhibitors and cardiac fibrosis: A comprehensive review","volume":"50","author":"Karakasis","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.eprac.2026.09.007_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejim.2024.09.020","article-title":"Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing","volume":"131","author":"Karakasis","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib31","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/dom.16303","article-title":"Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study","volume":"27","author":"Tesfaye","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.09.007_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.34067\/KID.0000000728","article-title":"The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters: A Retrospective Cohort Study","volume":"6","author":"Schaub","year":"2025","journal-title":"Kidney360"},{"key":"10.1016\/j.eprac.2026.09.007_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41591-024-03330-x","article-title":"Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial","volume":"31","author":"Anderegg","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.8","article-title":"Kidney stones","volume":"2","author":"Khan","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.eprac.2026.09.007_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I(2) is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eprac.2026.09.007_bib36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.EDE.0000042804.12056.6C","article-title":"Quantifying biases in causal models: classical confounding vs collider-stratification bias","volume":"14","author":"Greenland","year":"2003","journal-title":"Epidemiology"},{"key":"10.1016\/j.eprac.2026.09.007_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.09.007_bib38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a112408","article-title":"Bias due to misclassification in the estimation of relative risk","volume":"105","author":"Copeland","year":"1977","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eprac.2026.09.007_bib39","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/sim.5453","article-title":"Quantifying the impact of between-study heterogeneity in multivariate meta-analyses","volume":"31","author":"Jackson","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.eprac.2026.09.007_bib40","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:56:58Z","timestamp":1793296618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26011493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S1530891X26011493"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitors and Nephrolithiasis Risk in Adults With Type 2 Diabetes: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}